21:59 , Dec 6, 2018 |  BC Week In Review  |  Clinical News

Yumanity reveals Parkinson's candidate as first compound from yeast platform

Yumanity Therapeutics LLC (Cambridge, Mass.) and colleagues used the company's yeast platform to identify inhibitors of the enzyme stearoyl-CoA desaturase-1 (SCD1) that could prevent α-synuclein toxicity in Parkinson's disease. The SCD1 inhibitors are the first...
23:59 , Dec 4, 2018 |  BC Extra  |  Preclinical News

Yumanity reveals Parkinson's candidate as first compound from yeast platform

Yumanity Therapeutics LLC (Cambridge, Mass.) and colleagues used the company's yeast platform to identify inhibitors of the enzyme stearoyl-CoA desaturase-1 (SCD1) that could prevent α-synuclein toxicity in Parkinson's disease. The SCD1 inhibitors are the first...
11:26 , Sep 28, 2018 |  BC Extra  |  Preclinical News

Two strategies block immune-mediated metastases in mice

Cold Spring Harbor Laboratory researchers and a team from two Italian institutions have published two different strategies to fight immune-mediated lung metastases. Dormant cancer cells can persist for years before awakening and proliferating, leading to...
01:50 , Sep 14, 2018 |  BC Innovations  |  Targets & Mechanisms

Repeat offenders

Dozens of intractable DNA repeat-driven diseases could boil down to a common problem: disrupted boundaries between chromatin domains, according to a study from the University of Pennsylvania. The results present new opportunities for diseases like...
00:52 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

RNA party

A study in Cell has uncovered a brain regulatory network involving a circular RNA, a long non-coding RNA and two microRNAs, and could provide some much needed insights in a field where finding links to...
19:31 , Jun 1, 2018 |  BC Week In Review  |  Financial News

CAMP4 Therapeutics launches with $30M series A

CAMP4 Therapeutics Corp. (Cambridge, Mass.) launched on May 31 with an untranched $30 million series A round led by new investor Andreessen Horowitz. Existing investors The Kraft Group and Polaris Partners also participated. A CAMP4...
12:31 , May 31, 2018 |  BC Extra  |  Financial News

CAMP4 Therapeutics launches with $30M series A

CAMP4 Therapeutics Corp. (Cambridge, Mass.) launched with an untranched $30 million series A round led by new investor Andreessen Horowitz. Existing investors The Kraft Group and Polaris Partners also participated. A CAMP4 spokesperson told BioCentury...
23:23 , May 4, 2018 |  BC Extra  |  Preclinical News

PPAR agonist-induced fatty acid metabolism boosts tissue regeneration

Scientists at the Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology published a paper in Cell Stem Cell showing that fatty acid oxidation (FAO) induced by short-term fasting promotes tissue regeneration and repair,...
22:43 , Apr 24, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models Mice harboring dormant breast cancer cells could be used to screen therapies to treat early metastatic relapse after breast cancer surgery. The model involves injecting mice subcutaneously with a line of dormant...
23:09 , Apr 17, 2018 |  BC Extra  |  Preclinical News

Salk creates brain organoids with functional blood vessels

Researchers at the Salk Institute for Biological Studies created human brain organoids that recruited and developed functional blood vessels when grafted into mice. The approach could help develop organoid models that come closer to mirroring...